Developer of gene therapies for congestive heart failure and type 2 diabetes. The company’s lead product, RT-100 for congestive heart failure (CHF) is a single-dose treatment designed to safely improve heart function. The second candidate for diabetes, RT-200, delivers a therapeutic gene – urocortin 2 – using a single intravenous injection. The company is also developing RT 400, a peptide therapy for acute decompensated heart failure. Founded in 2009, headquartered in San Diego, United States. The company has raised $7.7M at the Series C stage backed by investors including NIH, HHS, K3, BioBrit. Operating in Life Sciences > Genomics, Life Sciences > Gene Therapy.
← All startups
Renova Therapeutics
Series CDeveloper of gene therapies for congestive heart failure and type 2 diabetes. The company’s lead product, RT-100 for congestive heart failure (CHF) is a single-dose treatment designed to safely improve heart function. The second candidate for diabetes, RT-200, delivers a therapeutic gene – urocortin 2 – using a single intravenous injection. The company is also developing RT 400, a peptide therapy for acute…
About
Business model
Diabetes > Drugs,
Cardiac and Vascular Disorders > Drugs > Heart Failure,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
NIHHHSK3BioBrit
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.